The new artificial intelligence-powered software reportedly helps detect central pulmonary embolism (PE) on computed tomography pulmonary angiogram (CTPA) images and streamlines communication among interventional teams to bolster treatment outcomes.
Could an emerging artificial intelligence (AI)-enabled triage platform facilitate earlier detection and treatment for people who suffer a pulmonary embolism (PE)?
The Rapid PE Triage & Notification product has garnered 510(k) clearance from the Food and Drug Administration (FDA), according to the product’s manufacturer RapidAI.
The AI-enabled platform reportedly offers a variety of key benefits in the diagnosis and treatment of PE.
• Enhanced identification of suspected central PE on computed tomography pulmonary angiogram (CTPA) images
• Real-time notification with previews of CTPA imaging available for review via mobile devices, desktop computers and laptops
• Streamlined communication among interventional teams to facilitate triage of priority cases and timely treatment
“I’m excited to see firsthand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” noted Jimmy Kerrigan, MD, FSCAI, FACC, RPVI, an interventional cardiologist affiliated with Ascension Saint Thomas Heart at multiple locations in Tennessee. “After seeing what RapidAI technology has done for stroke, I’m optimistic about about its potential to optimize our care for patients and to hopefully improve patient outcomes.”
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.